The impact of the use of multiple risk indicators for fracture on case-finding strategies: a mathematical approach. Osteoporos Int 2005 Mar; 16(3): 313–8PubMedCrossRef 13. González Macías J, Guañabens Gay N, Gómez Alonso C, et al. Guías de práctica clínica en la osteoporosis posmenopáusica, glucocorticoidea y del varón. Sociedad Española De Investigación Ósea Y Del Metabolismo Mineral. Rev Clin Esp 2008 May; 208 (Suppl. 1): 1–24CrossRef 14. Watts NB, Bilezikian JP, Camacho PM, et al. American Association of Clinical Endocrinologists medical guidelines
for clinical practice for the diagnosis and treatment of postmenopausal osteoporosis: executive summary of recommendations. Endocr Pract 2010 Nov–Dec; 16(6): 1016–9PubMedCrossRef 15. Papaioannou A, Morin S, Cheung AM, et al. 2010 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada: summary. CMAJ 2010 Nov 23; 182(17): 1864–73PubMedCrossRef 16. Compston J, Cooper A, Cooper C, JQ1 ic50 et al. Guidelines for the diagnosis and management of osteoporosis in postmenopausal women and men from the age of 50 years in the UK. Maturitas 2009 Feb 20; 62(2): 105–8PubMedCrossRef 17. Kanis JA, Burlet N, Cooper C, et al. European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int
2008 Apr; 19(4): 399–428PubMedCrossRef 18. Kanis JA, Torgerson D, Cooper C. Comparison of the European and USA practice guidelines for osteoporosis. Trends Endocrinol Metab 2000 Jan–Feb; 11(1): 28–32PubMedCrossRef
19. Vos E. Osteoporosis guidelines GSK872 manufacturer miss big picture. CMAJ 2011 Apr 5; 183(6): 695PubMed 20. Crabtree NJ, Bebbington NA, Chapman DM, et al. Impact of UK national guidelines based Pyruvate dehydrogenase lipoamide kinase isozyme 1 on FRAX®—comparison with current clinical practice. Clin Endocrinol (Oxf) 2010 Oct; 73(4): 452–6 21. Jódar Gimeno E. Conclusiones consensuadas del I Foro Multidisciplinar en el Manejo del Paciente con Alto Riesgo de Fractura (ARF) Osteoporótica. Rev Osteoporos Metab Miner 2010 Jul; 2(2): 79–86 [online]. Available from URL: http://www.revistadeosteoporosisymetabolismomineral.com/pdf/ACY-241 molecular weight articulos/12010020200790086.pdf [Accessed 2012 Nov 15] 22. Hosking D, Alonso CG, Brandi ML. Management of osteoporosis with PTH: treatment and prescription patterns in Europe. Curr Med Res Opin 2009 Jan; 25(1): 263–70PubMedCrossRef 23. Jódar-Gimeno E. Full length parathyroid hormone (1–84) in the treatment of osteoporosis in postmenopausal women. Clin Interv Aging 2007; 2(1): 163–74PubMedCrossRef 24. Gil VF, Belda J, Munoz C, et al. Validity of four indirect methods which evaluate therapeutic compliance for arterial hypertension. Rev Clin Esp 1993 Nov; 193(7): 363–7PubMed 25. Appraisal of Guidelines, Research, and Evaluation in Europe (AGREE) Collaborative Group. Guideline development in Europe: an international comparison. Int J Technol Assess Health Care 2000 Autumn; 16(4): 1039–49CrossRef 26. AGREE Collaboration.
Related posts:
- J Bone Miner Res 25:1886–1894PubMedCrossRef
21 Ominsky M - cfm#MP_2583 [Accessed 1 July 2011] 49 Borgstrom F, Strom O, K
- N Engl J Med 335:1016–1021PubMedCrossRef 37 Naylor G, Davies MH
- Vertebroplasty does not play a role in further fracture preventio
- The objective was to apply the proposed prescribing indicators to